
|Videos|March 17, 2022
Dr. Min Dong discusses ongoing research with onabotulinumtoxinA for patients with urologic disease
Author(s)Urology Times staff
“Botox has been a wonderful drug for many, many years,” says Min Dong, MD.
Advertisement
In this video, Min Dong, MD, summarizes the ongoing and future research related to Botox therapies for urologic diseases. These ideas stem from the talk he gave at the Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction 2022 Winter Meeting, titled, “New frontiers in therapeutic toxins for urologic disease.” Dong is an associate professor of urology at Harvard Medical School in Cambridge, Massachusetts.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
The UroOnc Minute: Cribriform Histology in Prostate Cancer, With Tyler Seibert, MD, PhD
2
CMS' 2027 PFS proposed rule: Modifier -25 cuts, G2211 overhaul loom
3
Rezūm shows greater 1-year BPH symptom relief vs pharmacotherapy
4
FDA grants breakthrough therapy, fast track designations to kidney cancer imaging agent
5










